The biotech sector in 2025 presents a landscape brimming with both opportunities and challenges. The industry is being shaped ...

William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...

In this article, we are going to take a look at where Denali Therapeutics, Inc. (NASDAQ:DNLI) stands against other biotech ...

Denali Therapeutics showcases its BBB platform at J.P. Morgan Conference, highlighting DNL310's Hunter syndrome progress and plans for commercialization.

Check the time stamp on this data. Updated AI-Generated Signals for Denali Therapeutics Inc. (DNLI) available here: DNLI.

Denali Therapeutics (NASDAQ:DNLI) on Monday said cash, cash equivalents, and marketable securities were approximately $1.28 billion as of September 30, 2024. Denali anticipates its cash runway will ...

DNLI opened at $21.25 on Tuesday. The stock has a fifty day moving average of $24.23 and a 200-day moving average of $24.86. Denali Therapeutics has a fifty-two week low of $14.56 and a fifty-two ...

NASDAQ:DNLI opened at $21.25 on Friday. Denali Therapeutics Inc. has a one year low of $14.56 and a one year high of $33.33. The company has a fifty day moving average price of $24.23 and a 200 ...